Author

Matthew J. Wakefield

The University of MelbourneORCID 0000-0001-6624-4698Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Genomics· 1 Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:benchmark study· 1 Research Focus:cell type annotation· 1 Research Focus:database / resource· 1 Research Focus:differential expression· 1

Frequent Co-Authors

Cassandra J. VandenbergiD· 3 shared Clare L. ScottiD· 3 shared Ksenija NesiciD· 3 shared Nicola WaddelliD· 3 shared Olga KondrashovaiD· 3 shared Sally BeardiD· 3 shared Alan F. RubiniD· 2 shared Alexander DobroviciD· 2 shared

Activity by Year

2021-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Cassandra J. VandenbergORCID

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Genomic alterations enable BRCA1 methylation loss and promoter bypass to drive resistance in high-grade serous ovarian cancer

Longyun Xu, Ksenija Nesic, Sally Beard, Jacinta L. Simmons, Xue Lu, Cassandra J. Vandenberg, Sharon M. Hoyte, Binny Jaradi, Ratana Lim, Franziska Geissler, Stacey L. Edwards, Joep Vissers, Anthony T. Papenfuss, Sean Michael Grimmond, John V. Pearson, , Olga Kondrashova

This study identifies genomic mechanisms enabling BRCA1 methylation loss and promoter bypass in ovarian cancer, leading to PARP inhibitor resistance.

bioRxiv · Jul 30, 2026 · PreprintCancer Biology

Demethylating agents drive PARP inhibitor resistance in ovarian carcinomas with BRCA1 gene silencing

Ksenija Nesic, Franziska Geissler, Lijun Xu, Elizabeth L. Kyran, Sally Beard, Cassandra J. Vandenberg, Brett Liddell, Sam W.Z. Olechnowicz, Monique D. Topp, Orla McNally, Gayanie Ratnayake, Nadia Traficante, Australian Ovarian Cancer Study, Anna DeFazio, David D.L. Bowtell, , Matthew J. Wakefield

This study shows that DNMT1 inhibitors reduce BRCA1 promoter methylation in HGSOC, leading to BRCA1 re-expression and PARP inhibitor resistance.

bioRxiv · Apr 7, 2025 · PreprintCancer Biology

Generation of a PARPi-sensitive homozygous BRCA1-methylated OVCAR8 cell line using targeted CRISPR gene editing

Ksenija Nesic, Sally Beard, Lijun Xu, Olga Kondrashova, Cassandra J. Vandenberg, Alan F. Rubin, Fan Zhang, Alexander Dobrovic, Nicola Waddell, Clare L. Scott, Kristy Shield‐Artin, Matthew J. Wakefield

The paper generates a homozygous BRCA1-methylated OVCAR8 cell line using CRISPR editing to study meBRCA1 stability and PARPi resistance.

bioRxiv · Sep 23, 2024 · PreprintCancer Biology

Non-canonical RNA substrates of Drosha lack many of the conserved features found in primary microRNA stem-loops

Karen Gu, Lawrence Mok, Matthew J. Wakefield, Mark M. W. Chong

This study identifies non-canonical Drosha substrates in mouse ESCs, showing they differ from miRNA stem-loops in processing efficiency, stability, and cleavage features.

Scientific Reports · Mar 20, 2024Peer-reviewedMolecular Biology

MaveDB v2: a curated community database with over three million variant effects from multiplexed functional assays

Alan F. Rubin, Joseph Min, Nathan J. Rollins, Estelle Y. Da, Daniel Esposito, Matthew Harrington, Jeremy Stone, Aisha Haley Bianchi, Mafalda Dias, Jonathan Frazer, Yunfan Fu, Molly Gallaher, Iris Li, Olivia G. Moscatelli, Jesslyn Ong, , Douglas M. Fowler

MaveDB v2 curates over three million variant effects from MAVE studies to facilitate analysis and dissemination of functional assay data.

bioRxiv · Nov 29, 2021 · PreprintGenomics